JP2013503642A5 - - Google Patents

Download PDF

Info

Publication number
JP2013503642A5
JP2013503642A5 JP2012528058A JP2012528058A JP2013503642A5 JP 2013503642 A5 JP2013503642 A5 JP 2013503642A5 JP 2012528058 A JP2012528058 A JP 2012528058A JP 2012528058 A JP2012528058 A JP 2012528058A JP 2013503642 A5 JP2013503642 A5 JP 2013503642A5
Authority
JP
Japan
Prior art keywords
interferon
antibody
subject
cdna
agent
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2012528058A
Other languages
English (en)
Japanese (ja)
Other versions
JP2013503642A (ja
JP5727484B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2010/047721 external-priority patent/WO2011028933A1/en
Publication of JP2013503642A publication Critical patent/JP2013503642A/ja
Publication of JP2013503642A5 publication Critical patent/JP2013503642A5/ja
Application granted granted Critical
Publication of JP5727484B2 publication Critical patent/JP5727484B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2012528058A 2009-09-03 2010-09-02 I型インターフェロン診断法 Expired - Fee Related JP5727484B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US23963009P 2009-09-03 2009-09-03
US61/239,630 2009-09-03
PCT/US2010/047721 WO2011028933A1 (en) 2009-09-03 2010-09-02 Type 1 interferon diagnostic

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2015075518A Division JP2015147788A (ja) 2009-09-03 2015-04-02 I型インターフェロン診断法

Publications (3)

Publication Number Publication Date
JP2013503642A JP2013503642A (ja) 2013-02-04
JP2013503642A5 true JP2013503642A5 (https=) 2013-10-17
JP5727484B2 JP5727484B2 (ja) 2015-06-03

Family

ID=43649646

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2012528058A Expired - Fee Related JP5727484B2 (ja) 2009-09-03 2010-09-02 I型インターフェロン診断法
JP2015075518A Pending JP2015147788A (ja) 2009-09-03 2015-04-02 I型インターフェロン診断法

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2015075518A Pending JP2015147788A (ja) 2009-09-03 2015-04-02 I型インターフェロン診断法

Country Status (23)

Country Link
US (3) US20120251546A1 (https=)
EP (1) EP2473636B1 (https=)
JP (2) JP5727484B2 (https=)
KR (1) KR20120101340A (https=)
CN (1) CN102753704A (https=)
AU (1) AU2010289383B2 (https=)
BR (1) BR112012004781A2 (https=)
CA (1) CA2772921A1 (https=)
CY (1) CY1118566T1 (https=)
DK (1) DK2473636T3 (https=)
ES (1) ES2613055T3 (https=)
HR (1) HRP20170091T1 (https=)
HU (1) HUE032917T2 (https=)
LT (1) LT2473636T (https=)
ME (1) ME02599B (https=)
MX (1) MX2012002640A (https=)
PL (1) PL2473636T3 (https=)
PT (1) PT2473636T (https=)
RS (1) RS55641B1 (https=)
RU (1) RU2012112802A (https=)
SI (1) SI2473636T1 (https=)
SM (2) SMT201700063T1 (https=)
WO (1) WO2011028933A1 (https=)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2488632A1 (en) * 2002-06-11 2003-12-18 Idaho Research Foundation Type i interferon-inducible proteins to detect viral infection
EP2077858A4 (en) * 2006-12-06 2011-07-20 Medimmune Llc INTERFERON ALPHA-INDUCED PHARMACODYNAMIC MARKERS
EP2076590A4 (en) * 2007-05-03 2011-06-01 Medimmune Llc SELF-IMMUNE DISEASE SELF-ANTIBODY MARKERS
AU2012249601A1 (en) * 2011-04-26 2013-05-09 Genentech, Inc. Compositions and method for treating autoimmune diseases
WO2013101771A2 (en) * 2011-12-30 2013-07-04 Genentech, Inc. Compositions and method for treating autoimmune diseases
AU2013274389A1 (en) * 2012-06-13 2015-01-22 Astrazeneca Ab Fixed dosage regimens for anti-type I interferon receptor (IFNAR) antibodies
JP6531306B2 (ja) * 2015-02-20 2019-06-19 一三 西野 炎症性筋疾患鑑別マーカー及びそれを用いた炎症性筋疾患と非炎症性筋疾患の鑑別方法
CN105316404B (zh) * 2015-02-27 2017-02-22 中南大学湘雅二医院 系统性红斑狼疮生物标志物及其诊断试剂盒
RU2756109C2 (ru) 2016-03-10 2021-09-28 Виела Байо, Инк. Связывающие ilt7 молекулы и способы их применения
CN105567861B (zh) * 2016-03-16 2018-12-14 宫蕊 Ifi27作为冠心病诊断标志物的用途
EP3924383A1 (en) * 2019-02-15 2021-12-22 Astrazeneca AB Type i interferon-mediated disorders
KR102766960B1 (ko) 2019-11-11 2025-02-11 아스트라제네카 아베 전신성 홍반성 루푸스에서 i형 인터페론 억제
CN115667309A (zh) 2020-05-29 2023-01-31 阿斯利康(瑞典)有限公司 使用i型干扰素信号传导的抑制剂治疗心血管代谢疾病
AR123650A1 (es) * 2020-10-02 2022-12-28 Celgene Corp Métodos para el tratamiento del lupus eritematoso sistémico y el uso de biomarcadores como un predictor de sensibilidad clínica a terapias
TW202237647A (zh) 2020-10-08 2022-10-01 瑞典商阿斯特捷利康公司 狼瘡發作之治療
JP2023549872A (ja) 2020-11-18 2023-11-29 アストラゼネカ・アクチエボラーグ ステロイド節約
PT4192882T (pt) 2021-04-23 2025-05-02 Astrazeneca Ab Tratamento de nefrite lúpica com anticorpo anifrolumab de recetor inf anti-tipo i
BR112023021868A2 (pt) 2021-04-23 2023-12-19 Astrazeneca Ab Tratamento de lúpus eritematoso cutâneo
HRP20231255T1 (hr) 2021-04-23 2024-02-02 Astrazeneca Ab Režim doziranja anti-ifnar1 za potkožnu injekciju
IL308132A (en) * 2021-05-04 2023-12-01 Viela Bio Inc Methods of treatment of autoimmune disorders using ilt7 binding proteins
US20250002591A1 (en) 2021-05-12 2025-01-02 Astrazeneca Ab Inhibitor of type 1 interferon receptor steroid sparing in systemic lupus erythermatosus patients
CA3226744A1 (en) 2021-07-27 2023-02-02 Astrazeneca Ab Treatment of lupus
WO2023057369A2 (en) 2021-10-04 2023-04-13 Astrazeneca Ab Treatment of lupus
EP4587005A1 (en) 2022-09-14 2025-07-23 Viatris Asia Pacific Pte. Ltd. Sip 1 receptor modulators for use in the treatment of type 1 ifn mediated diseases
JP2025533978A (ja) 2022-10-13 2025-10-09 アストラゼネカ・アクチエボラーグ ループスの治療
CN121127499A (zh) 2023-05-19 2025-12-12 阿斯利康(瑞典)有限公司 狼疮的治疗
WO2025022280A1 (en) 2023-07-21 2025-01-30 Astrazeneca Ab Treatment of neurodegenerative diseases
GB202315831D0 (en) 2023-10-16 2023-11-29 Astrazeneca Ab Treatment of skin disease
GB202402824D0 (en) 2024-02-28 2024-04-10 Astrazeneca Ab Treatment of chronic kidney disease

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0139676B1 (en) 1983-02-04 1992-11-25 Cytoclonal Pharmaceutics Inc. Production and characterization of hybridoma antibodies directed specifically against common determinant(s) present among closely related, but distinct proteins
GB8303165D0 (en) 1983-02-04 1983-03-09 Secher D S Monoclonal antibody
DE3306060A1 (de) 1983-02-22 1984-08-23 Boehringer Ingelheim International GmbH, 6507 Ingelheim Neue immunglobulin-produzierende hybridzellinien, deren verwendung und verfahren zu deren herstellung
EP0205404B1 (en) 1985-06-11 1992-07-15 Ciba-Geigy Ag Hybrid interferons
US7247425B2 (en) * 1998-01-30 2007-07-24 Evolutionary Genomics, Llc Methods to identify polynucleotide and polypeptide sequences which may be associated with physiological and medical conditions
US7087726B2 (en) 2001-02-22 2006-08-08 Genentech, Inc. Anti-interferon-α antibodies
JP2008500009A (ja) * 2003-03-03 2008-01-10 ジェネンテック・インコーポレーテッド 全身性エリテマトーデスの治療のための組成物と方法
CA2458085A1 (en) * 2003-03-21 2004-09-21 F. Hoffmann-La Roche Ag Transcriptional activity assay
KR100872210B1 (ko) 2003-04-23 2008-12-05 메다렉스, 인코포레이티드 인터페론 알파 수용체-1 (ifnar-1)에 대한 인체화항체
NZ547157A (en) 2003-12-10 2009-07-31 Medarex Inc Interferon Alpha Antibodies and their uses
US8019552B2 (en) * 2004-03-05 2011-09-13 The Netherlands Cancer Institute Classification of breast cancer patients using a combination of clinical criteria and informative genesets
HUE035082T2 (en) 2004-06-21 2018-05-02 Squibb & Sons Llc Interferon alpha receptor 1 antibodies and their use
PT2327792E (pt) * 2005-08-05 2013-11-21 Genentech Inc Métodos e composições para a detecção de distúrbios autoimunes
US8211649B2 (en) * 2006-03-31 2012-07-03 Human Genome Sciences, Inc. Methods of diagnosing and prognosing hodgkin's lymphoma
US20100120627A1 (en) * 2006-08-02 2010-05-13 Abdelmajid Belouchi Genemap of the human genes associated with psoriasis
EP2077858A4 (en) * 2006-12-06 2011-07-20 Medimmune Llc INTERFERON ALPHA-INDUCED PHARMACODYNAMIC MARKERS
EP2076590A4 (en) * 2007-05-03 2011-06-01 Medimmune Llc SELF-IMMUNE DISEASE SELF-ANTIBODY MARKERS
US20100209914A1 (en) * 2007-05-25 2010-08-19 Ore Pharmaceuticals , Inc. Methods, systems, and kits for evaluating multiple sclerosis
SG188147A1 (en) * 2008-02-08 2013-03-28 Medimmune Llc Disease markers and uses thereof
WO2009130176A1 (en) * 2008-04-21 2009-10-29 Novartis Forschungsstiftung Zweigniederlassung Friedrich Miescher Institute For Biomedical Research Antiviral Therapy
WO2009149319A2 (en) * 2008-06-05 2009-12-10 Wyeth Gene expression profiles associated with asthma exacerbation attacks

Similar Documents

Publication Publication Date Title
JP2013503642A5 (https=)
HRP20170091T1 (hr) Dijagnostika interferona tip 1
JP2012518421A5 (https=)
JP2010529857A5 (https=)
JP2019196400A5 (https=)
JP2012531202A5 (https=)
EP2603605B1 (en) A method for classifying an inflammatory bowel disease as a crohn's disease or as an ulcerative colitis
JP2010526107A5 (https=)
JP2014509862A5 (https=)
JP2011101652A5 (https=)
JP2020505920A5 (https=)
JP2010535480A5 (https=)
JP2009523005A5 (https=)
JP2012514451A5 (https=)
MX346956B (es) Captura directa, amplificación y secuenciación de objetivo adn usando cebadores inmovilizados.
JP2012503985A5 (https=)
JP2016537990A5 (https=)
JP2010035552A5 (https=)
JP2009544314A5 (https=)
WO2006029184A3 (en) Genes useful for diagnosing and monitoring inflammation related disorders
JP2015528294A5 (https=)
JP2006518186A5 (https=)
JP2012507293A5 (https=)
JP2017521654A5 (https=)
JP2005511023A5 (https=)